Replies to post #95073 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

That's a great question that I hope a few of the savvy long term DDers would address further. I think the two drivers are one that Elite's ART studies continue to progress towards Phase III trials and the continued market share Elite will be able to continue to capture on their 20 already marketed or approved Andas.

Anything higher than $2.75 would need to be in relation to a Big Pharma partnership and Elite having the ability to market their ART products.

So I do think the two drivers would be the market looking forward to their current products and continued success on their ART studies.